Literature DB >> 24965812

Inflammatory bowel disease alters intestinal bile acid transporter expression.

Jörg Jahnel1, Peter Fickert2, Almuthe C Hauer2, Christoph Högenauer2, Alexander Avian2, Michael Trauner2.   

Abstract

The enterohepatic circulation of bile acids (BAs) critically depends on absorption of BA in the terminal ileum and colon, which can be affected by inflammatory bowel disease (IBD). Diarrhea in IBD is believed to result in part from BA malabsorption (BAM). We explored whether IBD alters mRNA expression of key intestinal BA transporters, BA detoxifying systems, and nuclear receptors that regulate BA transport and detoxification. Using real-time polymerase chain reaction, mucosal biopsy specimens from the terminal ileum in Crohn's disease (CD) patients and from the descending colon in ulcerative colitis (UC) patients were assessed for mRNA expression. Levels were compared with healthy controls. The main ileal BA uptake transporter, the apical sodium dependent bile acid transporter, was downregulated in active CD and UC and in CD in remission. Other significant changes such as repression of breast cancer-related protein and sulphotransferase 2A1 were seen only during active disease. In UC, pancolitis (but not exclusively left-sided colitis) was associated with altered expression of major BA transporters [multidrug resistance-associated protein 3 (MRP3), MRP4, multidrug resistance gene 1, organic solute transporter α/β] and nuclear receptors (pregnane X receptor, vitamin D receptor) in the descending colon. UC pancolitis leads to broad changes and CD ileitis to selective changes in intestinal BA transporter expression. Early medical manipulation of intestinal BA transporters may help prevent BAM.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24965812     DOI: 10.1124/dmd.114.058065

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  32 in total

Review 1.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.

Authors:  Aonghus Lavelle; Harry Sokol
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-19       Impact factor: 46.802

2.  Ursodeoxycholic acid exerts hepatoprotective effects by regulating amino acid, flavonoid, and fatty acid metabolic pathways.

Authors:  Da Jung Kim; Hyewon Chung; Sang Chun Ji; SeungHwan Lee; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  Metabolomics       Date:  2019-02-27       Impact factor: 4.290

Review 3.  Intestinal Absorption of Bile Acids in Health and Disease.

Authors:  Alexander L Ticho; Pooja Malhotra; Pradeep K Dudeja; Ravinder K Gill; Waddah A Alrefai
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

4.  Ten Reasons to Think about Bile Acids in Managing Inflammatory Bowel Disease.

Authors:  Michael Camilleri
Journal:  J Crohns Colitis       Date:  2020-08-31       Impact factor: 9.071

5.  5-Aminosalicylic acid ameliorates dextran sulfate sodium-induced colitis in mice by modulating gut microbiota and bile acid metabolism.

Authors:  Ling Huang; Junping Zheng; Guangjun Sun; Huabing Yang; Xiongjie Sun; Xiaowei Yao; Aizhen Lin; Hongtao Liu
Journal:  Cell Mol Life Sci       Date:  2022-08-01       Impact factor: 9.207

6.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

Review 7.  Update on Bile Acid Malabsorption: Finally Ready for Prime Time?

Authors:  Priya Vijayvargiya; Michael Camilleri
Journal:  Curr Gastroenterol Rep       Date:  2018-03-26

8.  Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling.

Authors:  Avafia Y Dossa; Oswaldo Escobar; Jamie Golden; Mark R Frey; Henri R Ford; Christopher P Gayer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-25       Impact factor: 4.052

9.  Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.

Authors:  Aliya F Gulamhusein; John E Eaton; James H Tabibian; Elizabeth J Atkinson; Brian D Juran; Konstantinos N Lazaridis
Journal:  Am J Gastroenterol       Date:  2016-03-22       Impact factor: 10.864

10.  Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products.

Authors:  Jiayu Ye; Lauren A E Erland; Sandeep K Gill; Stephanie L Bishop; Andrea Verdugo-Meza; Susan J Murch; Deanna L Gibson
Journal:  Biomolecules       Date:  2021-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.